Regulation of Rad51 Nucleoprotein Filament Formation and Genomic Stability
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 2248
Special Issue Editor
Interests: replication; helicases; mediator proteins; genome stability; DNA Repair; rad51 filament; homologous recombination
Special Issue Information
Dear Colleagues,
Homologous recombination (HR) is a critical pathway for DNA double-strand break repair, present in all forms of life. In eukaryotes, HR requires the presence of recombinase RAD51 filaments on single-stranded DNA. These filaments scan the genome for double-stranded DNA homologous sequences used as a template for DNA repair synthesis. RAD51 nucleoprotein filament formation, stability and dissociation implicate complex management of ATP uptake and hydrolysis by the recombinase. These processes also involve the action of numerous positive regulators that were unveiled in a broad range of biological models across yeasts, plants and animals. Rad52 in yeast and BRCA2 in metazoans are the main loaders mediating nucleation and RAD51 filament growth which also require RAD51 paralog proteins. In yeast, these positive regulators have been shown to limit the activity of the SF1 helicase/translocase Srs2, a negative regulator of Rad51 filament assembly. Numerous functional homologs of Srs2 have been identified in higher eukaryotes, suggesting that RAD51 nucleofilament formation is fine-tuned by positive and negative activities throughout the eukaryotic domain. In humans, several RAD51 nucleofilament regulators have been associated with cancer, suggesting that RAD51 nucleofilament homeostasis is an important guardian of genome stability. The aim of this Special Issue on Biomedicines is to provide an overview of the state-of-the-art practice and promote new insights into the relationship between RAD51 filament regulation and genomic stability. Both original articles and reviews consistent with this research topic will be considered for publication in this Special Issue.
Dr. Eric Coïc
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
